anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention pertains to a medicine for treating onychomycosis, which is made of the traditional Chinese medicines. The formula of the medicine comprises the drugs with the parts by weight: 50 to 250 parts of brenstone, 50 to 300 parts of arsenic disulfide, 80 to 200 parts of borate, 30 to 200 parts of siberian solomonseal rhizome, 30 to 200 parts of chinaberry fruit and 30 to 200 parts of purslane; all drugs are mixed and then crushed or crushed and then mixed; then, the mixed powdery mixture is mixed with cooked lard to form a pasty medicine for treating onychomycosis. And also the water solution of the auxiliary drugs such as oxybenzoic acid, benzoic acid, cicada slough, safflower, urea, common myrrh tree, camphor, centipede, alum, dried alum and cantharides can be added to the pasty medicine. The medicine has the advantages that the medicine has persistent bactericidal action with the effect of a single dose lasting for 6 days, and has much better bactericidal action than the medicines only made from Chinese medicinal herbs due to the use of mineral drugs such as the brenstone, the arsenic disulfide and the borate. The medicine also has the advantages of small dose, convenient use and low expense. The medicine for treating onychomycosis in the invention can be used for treating other superficial dermatomycosis.
System and methods for maintaining a supply of health-related items are provided herein. The system includes, but is not limited to, a carrier configured to contain the health-related item. The system further includes, but is not limited to, a container having a compartment configured to store the carrier. The system includes, but is not limited to, an item presence sensor coupled to the container. The system includes, but is not limited to, a sensor tag coupled to carrier and configured to be communicatively coupled with the item presence sensor. The system includes, but is not limited to, one or more data processors configured to be communicatively coupled with the item presence sensor and configured to determine whether the health-related item is present within the container based upon proximity of the sensor tag to the item presence sensor.
PCT No. PCT/CN94/00080 Sec. 371 Date Dec. 13, 1996 Sec. 102(e) Date Dec. 13, 1996 PCT Filed Oct. 22, 1994 PCT Pub. No. WO95/11025 PCT Pub. Date Apr. 27, 1995The present invention involves a pharmaceutical composition for preventing and treating motion sickness syndrome, the method of using it to treat motion sickness syndrome and the method for preparing phencynonate hydrochloride of  alpha -configuration, the active component of the pharmaceutical composition. As compared with the known anti-motion sickness drugs, the pharmaceutical composition of the present invention showed higher efficacy and lower side effects. In addition, the pharmaceutical composition of the present invention can also be used for preventing and treating many symptoms of functional disorders of central and peripheral cholinergic system resulting from excessive central and peripheral acetyl choline.
FIELD: chemistry.SUBSTANCE: invention relates to a new tricyclic compound (variants) corresponding to the general formula I, II or III, or its pharmaceutically acceptable salt, which has inhibitory activity against JAK. Compounds can be used as a prophylactic, therapeutic agent or agent for alleviating diseases for which JAK inhibition is effective, in particular for the treatment of rheumatoid arthritis. Tricyclic compound corresponds to the formula (I), (II) or (III). In compound of formula (I) Arepresents Ccycloalkylene group, Lrepresents Calkylene group, Xrepresents O or NH, and when Xis O, Rrepresents Chaloalkyl group, cyano-Chaloalkyl group or cyano-Calkyl group, and when Xrepresents NH, Ris a cyano-Chaloalkyl group or cyano-Calkyl group. In the compound of formula (II) Arepresents Ccycloalkylene group, Lrepresents Calkylene group, Ris a 5-membered heteroaromatic group containing 2 nitrogen atoms in the ring (heterocyclic group may be substituted by one or two identical or different substituents independently selected from the group including halogen atoms, Calkyl groups and Chaloalkyl groups). In the compound of formula (III) Arepresents Ccycloalkylene group, Lpresents Calkylene group, Xrepresents O or NH, and when Xis O, Rrepresents Chaloalkyl group, cyano-Chaloalkyl group or cyano-Calkyl group, and when Xrepresents NH, Ris cyano-Chaloalkyl group or cyano-Calkyl group.EFFECT: tricyclic compound and an inhibitor of JAK are proposed.38 cl, 5 tbl, 41 ex
Multiple sclerosis (MS), traditionally perceived as a neurodegenerative disease, exhibits significant vascular alternations, including blood-brain barrier (BBB) disruption, which may predispose patients to increased cardiovascular risks. This vascular dysfunction is intricately linked with the infiltration of immune cells into the central nervous system (CNS), which plays a significant role in perpetuating neuroinflammation. Additionally, oxidative stress serves not only as a byproduct of inflammatory processes but also as an active contributor to neural damage. The synthesis of these multifaceted aspects highlights the importance of understanding their cumulative impact on MS progression. This review reveals that the triad of vascular damage, chronic inflammation, and oxidative imbalance may be considered interdependent processes that exacerbate each other, underscoring the need for holistic and multi-targeted therapeutic approaches in MS management. There is a necessity for reevaluating MS treatment strategies to encompass these overlapping pathologies, offering insights for future research and potential therapeutic interventions. Whole-body cryotherapy (WBCT) emerges as one of the potential avenues for holistic MS management approaches which may alleviate the triad of MS progression factors in multiple ways.
The utility model relates to a defervescing paster capable of displaying a fever state, and a display process is reversible. The paster comprises a state-displaying paster unit and a defervescing paster unit. The state-displaying paster unit is divided into three zones which are three different ranges of temperature. The state-displaying paster unit comprises a lower surface, an upper surface, a developing material, and a plastic film. The developing material is coated or put between the upper and lower surfaces. Meanwhile, the edges of the upper and lower surfaces are sealed. The outer side of the lower surface is coated with a non-setting adhesive, and then is covered by the plastic film. The paster also comprises a back lining layer, a gel layer, and a plastic film layer. The back lining layer is located at the uppermost layer, and the gel layer is uniformly coated on the back lining layer. The plastic film layer completely covers the gel layer. Moreover, the edge of the back lining layer, the edge of the gel layer and the edge of the plastic film layer are not sealed.
PURPOSE: A chitosan oligo saccharides derivative having BACE inhibition activities and a pharmaceutical composition for preventing or treating Alzheimer disease are provided to show excellent BACE inhibition activities. CONSTITUTION: A chitosan oligo saccharides derivative having phenolic acid is represented by chemical formula 1. In the chemical formula 1, R1 indicates H or OCH3, R2 indicates OH, and R3 indicates H, OH or OCH3. The chitosan oligo saccharides derivative having phenolic acid is represented by chemical formula 2. In the chemical formula 2, R1 indicates H or OCH3, R2 indicates OH, and R3 indicates H, OH or OCH3. A pharmaceutical composition for preventing or treating Alzheimer disease contains chitosan oligo saccharides having phenolic acid as the active ingredient.
The VALENTINE Cardiac Rehabilitation Study will evaluate a digital intervention to supplement cardiac rehabilitation for low- and moderate risk patients, integrating a mobile application with physiologic and contextual information from wearables to provide incremental support to patients. The study will be performed in conjunction with planned home-, hybrid-, or center-based cardiac rehabilitation at Michigan Medicine. Participants will be randomized to the control or telehealth group. Both groups will receive a smartwatch and usual care. Participants in the telehealth arm will additionally (1) have access to activity tracking and goal setting through the VALENTINE app; (2) receive micro-randomized, contextually tailored notifications, and (3) receive weekly activity summaries via email, which will also be provided to their exercise physiologist while enrolled in cardiac rehabilitation. Contextually tailored notifications will be one of two types: walking and exercise notifications. Walking notifications are designed to encourage participants to be active though at lower than their target heart rate zone. Participants will receive 1 notification per day, on average, at one of four times. Notifications will be randomized on four dimensions of context. Exercise notifications are designed to encourage participants to exercise within their target heart rate zone. Notifications will be delivered each evening at a time of the participant's choosing. Participants will have a 50% probability of receiving a notification each evening. Notifications will be randomized on two dimensions of context. Participants will be followed for 6-months. Participants in both arms will be asked to complete a 6-minute walk test at baseline, 3-months, and 6-months using their mobile phone and smartwatch. They will additionally complete general and disease-specific quality-of-life questionnaires at baseline and at 6-months.

To account for potential measurement error between devices, for primary and secondary analyses, we will perform regression analysis to jointly test the null hypothesis H0: B0(F) = B0(A) = 0 for change between baseline and 6 months where (F) and (A) refer to Fitbit and Apple watches respectively. A secondary analysis will subsequently be performed to determine whether to reject the individual null hypotheses for each of the two devices. For all statistical analyses, the level of significance will be set at p \<0.05.
Participants randomized to intermittent IFX/AZA were to receive IFX 5 mg/kg of body weight IV infusions only upon relapse of disease (initiated at Weeks 0, 2, and 6 of individual treatment cycle and continued every 8 weeks until remission was regained) plus AZA 2.5 mg/kg of body weight daily in Part 2 of the study. Three participants were from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study.
OBJECTIVES: Accurate puncture is the key to ensure the effect of puncture and drainage surgery for intracerebral hemorrhage. It usually uses CT to guide the drainage tube to reach the center of the hematoma cavity, which has the problems of inaccurate positioning using 2D images and high requirements for surgeon's experience in brain anatomy and imaging diagnosis. The aim of this study was to use a 3D printing puncture guide plate to guide the puncture and drainage surgery for intracerebral hemorrhage.
METHODS: The CT images were imported into 3D Slicer software to reconstruct 3D models of the head skin and intracerebral hematoma. The target was set in the center of the hematoma and the puncture path from the target to the entry point was designed, the 3D model of puncture guide plate was constructed and saved as stereolithography format file, which was imported into 3D printer to print. During surgery, the drainage tube was placed in the center of the hematoma guided by the 3D printing puncture guide plate, and the blood clot was extracted by the suction syringe.
RESULTS: Eight patients with hypertensive intracerebral hemorrhage were treated with puncture and drainage surgery guided by 3D printing puncture guide plate. The average operation time of the 8 surgeries was 17.63 minutes. The drainage tubes were all precisely placed in the center of the hematoma, and the blood clots were all successfully extracted. The positioning errors of the 8 drainage tubes were between 1.76 mm and 2.68 mm, and the mean value was 2.10±0.32 mm. The hematoma clearance rate of the 8 patients was between 74.18% and 96.73%, and the mean value was 85.14±6.71%.
CONCLUSIONS: The puncture and drainage surgery for intracerebral hemorrhage guided by 3D printing puncture guide plate helps to quickly and effortlessly localize intracerebral hematoma and achieves satisfactory hematoma clearance rate.
Internet-based treatment with therapist support using an asynchronous messaging system. The treatment is comprised of 12 modules (similar to chapters) and the treatment is 12 weeks long. The treatment is based on cognitive behavior therapy. Participants will be stratified based on diagnosis, i.e. adjustment disorder and burnout.
Training sessions will be overseen by a physiotherapist and will last for 1 hour over 4 consecutive days. Participants in the walking control group will complete 36 unperturbed walking trials on the moving platform in each training session.
All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.Within 4 hours of admission, the observation group were required to undergo nasogastric tube removal and initiated Intermittent Oro-Esophageal Tube Feeding for nutrition support.
Radiotherapy is an important treatment for esophageal cancer, and acute radiation-induced esophagitis (ARIE) is the most common complication during radiotherapy. The present study was conducted to investigate the clinical efficacy of deep-sea fish oil in the prevention and treatment of ARIE, and to evaluate the effects of deep-sea fish oil on patients' nutritional status, quality of life, pain management, and the effect on the treatment. This is a prospective, single-center, randomized controlled clinical study. The present study has been registered in the Chinese Clinical Trials Registry (ChiCTR2200056847). The present study intends to continuously enroll 120 patients with esophageal cancer who are to receive radiotherapy, and randomly divide the enrolled patients into two groups. One group receive treatment of deep-sea fish oil and the other group is blank control. The differences of ARIE occurrence, ARIE degree, pain degree, and the changes of the inflammatory index were compared.
Each pregnant woman in the placebo group is going to be informed about the grounding stick and how to use it, with a 2-minute video showing. Participants walk on the ground for 30 minutes daily and go on for four weeks. During the program, the pregnant women will be called to their homes every week and necessary reminders will be made.
The utility model relates to a skin care product with color balls, which comprises a transparent container with a cover; the container is filled with soft transparent skin care preparation. The utility model is characterized in that color balls formed by using a coating layer to coat skin care basic materials are mixed in the soft transparent skin care preparation. The color balls are dispersed in the soft transparent skin care preparation, such as gel, etc. The coating layer is made of sodium alginate purified from nature materials, pearl powder, pigment, etc., prevents the skin care basic materials in the color balls from deteriorating, oxidizing and inactivating, and avoids the interaction between skin care effective components and soft transparent bodies so as to influence the skin care effect of the effective components. The skin care basic materials in the coating layer comprise all the effective components, which are easier to quantify in use, is comfortable and even to smear, is good for absorbing and has good skin care effect. The skin care product has a plurality of types; the color balls has multiple colors or one color; consumers correspondingly identify the effective components of the skin food product according to the colors so as to select the type and the odor type of the skin care product required. The utility model is visual and simple, enhances skin care interests and is particularly suitable for juveniles and children.
Orbital cellulitis is an uncommon condition with risks to sight and life. As a complication of maxillofacial injuries, the literature suggests this is only possible with fractures or direct inoculation, and there are no reports to the contrary. Here, we make the first report of a possible etiology by which orbital cellulitis developed in a 14-year-old boy even without skin breach or bony fractures; as well as a rare causative pathogen. He presented with facial abscess and progressive orbital cellulitis after blunt facial trauma, requiring functional endoscopic sinus surgery with needle aspiration of facial abscess externally. Cultures showed growth of Streptococcus constellatus/Parvimonas micra, and he received further antibiotics with full recovery.The pathophysiology of orbital cellulitis in this patient is attributed to vascular congestion and local pressure from maxillofacial contusion and maxillary hemoantrum, with impaired paranasal sinus ventilation encouraging anaerobic bacterial growth. Further progression led to facial abscess formation and intraorbital spread with orbital cellulitis. The pediatric demographic is injury-prone, and self-reporting of symptoms can be delayed. Hence, increased suspicion of complicated injuries and orbital cellulitis may be required when managing maxillofacial contusions so that prompt treatment can be given.
This is a non-interventional, cross-sectional, multicentre, and multinational (European) study. The non-interventional study (NIS) design allows the observation of patients in large haemodialysis (HD) centres reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the full discretion of the treating physician without interference by the sponsor or study protocol. All treatment decisions will follow the real-life treatment behaviour.

The CENSUS-EU represents a cross-sectional study design of a representative selection of patients undergoing HD at 113 large dialysis centres across 7 countries in Europe. Prot. v.2.0, 9 May 2023
This is a study in Gulf War Veterans born between 1946 and 1978 who meet the modified Kansas and Centers for Disease Control and Prevention (CDC) case definitions for Gulf War Illness. This phase II, double-masked, randomized, placebo-controlled, two-arm study will focus on assessing cognitive function as evidence of efficacy of the nutraceutical intervention, Bacopa, on central nervous system symptom management of Gulf War Illness. 170 participants will be randomized 1:1 to receive either 12 weeks of the intervention (Bacopa) or placebo. Participants will be evaluated "remotely" via online assessment tools and telephone interviews, allowing participation from a nationwide catchment area. Primary assessment via the California Verbal Learning Test, Second Edition (CVLT-II) will occur at baseline and 12 weeks, along with laboratory assessments for all participants at baseline, and a self-selected subgroup at 12 weeks. Randomization to the intervention or placebo arms will be stratified by membership in the 12-week follow-up laboratory subgroup and sex. Laboratory draws will be performed at the participant's local clinical laboratory and will allow for measurements of putative biomarkers of neuron health and structural integrity along with biomarkers of inflammation and immune signaling. Monitoring phone calls will be made to the participant biweekly to assess safety. Participants will also undergo subjective assessments of physical health, vitality, sleep, pain, and symptom severity at baseline, 6, 12, and 16 weeks. Thus, participants will be observed through the treatment period (12 weeks) and for 4 weeks after completion to assess immediate effects and durability of the response.
Zonisamide, the active ingredient in ZONISADE, can have an effect on renal function. In several clinical studies, zonisamide was associated with a statistically significant 8% mean increase from baseline of serum creatinine and blood urea nitrogen (BUN) compared to essentially no change in the placebo patients. The increase appeared to persist over time but was not progressive; this has been interpreted as an effect on glomerular filtration rate (GFR). There were no episodes of unexplained acute renal failure in clinical development in the US, Europe, or Japan. The decrease in GFR appeared within the first 4 weeks of treatment. In a 30-day study, the GFR returned to baseline within 2–3 weeks of drug discontinuation. There is no information about reversibility, after drug discontinuation, of the effects on GFR after long-term use. ZONISADE should be discontinued in patients who develop acute renal failure or a clinically significant sustained increase in the creatinine/BUN concentration. Avoid use of ZONISADE in patients with renal failure (estimated GFR < 50 mL/min) since there is insufficient experience concerning drug dosing and toxicity [see Use in Specific Populations (8.6)]. Consideration should be given to monitoring renal function periodically.
PURPOSE:To obtain the titled solid free from the gastric damage caused by the oral administration of a non-steroidal anti-inflammatory agent, by compounding a pH-dependent polymeric compound to a non-steroidal anti- inflammatory agent. CONSTITUTION:The objective amorphous solid soluble in the intenstine, contains a non-steroidal anti-inflammatory agent (e.g. indomethacin) and one or more pH-dependent polymeric compounds (e.g. hydroxypropylene methylcellulose) at a weight ratio of 1:0.1-5. The oral administration of a non-steroidal anti- inflammatory agent occasionally causes gastric damage such as gastric ulcer, however, the above solid preparation causes little gastric damage even by oral administration. The solid can be prepared easily by dissolving a non-steroidal anti-inflammatory agent and one or more pH-dependent polymeric compounds in an organic solvent (eg. dichloromethane), and removing the organic solvent from the solution.
PROBLEM TO BE SOLVED: To provide a new antitumor composition which uses Campylaephora hypnaeoides as a raw material and is especially useful not only as edible fibers but also as the new use of the Campylaephora hypnaeoides, and to provide a method for producing the new antitumor composition. SOLUTION: This antitumor composition originated from Campylaephora hypnaeoides is characterized by being obtained as a powdery substance having all of the following physical properties (a) to (d). (a) The substance is white or pale brown powder and is easily soluble in water. (b) The substance has a saccharide composition comprising about 50% of neutral saccharides, several % of acidic saccharides, and 20% of anhydrogalactose, and does not contain a sulfate group. (c) The substance shows a proton-NMR(Nuclear Magnetic Resonance) spectrum, and shows a signal comprising only saccharides in the NMR. (d) The substance shows a band ranged from the starting point to 0.9 to 1.2 cm in a cellulose acetate membrane electrophoresis condition.